广州市人群乙型肝炎病毒感染模式与丙型肝炎病毒感染情况调查

为了解广州市人群乙型肝炎病毒（ＨＢＶ）与丙型肝炎病毒（ＨＣＶ）双重感染情况，对１９９３年４月体检中检出的１９３例ＨＢＶ标志物阳性血清归类分析，发现有１４种ＨＢＶ感染模式，其中以ＨＢｓＡｇ·ＨＢｅＡｂ·ＨＢｃＡｂ和ＨＢｓＡｇ·ＨＢｅＡｇ·ＨＢｃＡｂ为多见，阳性模式构成分别为４３．０１％和３０．５７％。在ＨＢＶ感染者中ＨＣＶ感染的检出率为１１．３９％（２２／１９３）．不同ＨＢＶ感染模式组别的抗－ＨＣＶ阳性率差异有统计学显著意义（ｐ＜０．００１）．     

Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations

The epidemiological situation calls for almost yearly changes in the antigenic composition of influenza vaccine, thus necessitating fresh licensing procedures. Since the time for bringing a new vaccine onto the market should be relatively short, the following work of all parties involved must be done expeditiously: 1) WHO recommendations on new virus strains and their subsequent adaptation by the EEC (February/March); 2) Distribution of the new virus strains to the International Reference Centers for Influenza in the UK and USA (February/ March); the centers later issue reference materials for the determination of the haemagglutinin antigen concentration (April/May); 3) Production and testing of seed virus by manufacturers, as well as validation of the producer's inactivation process for the new virus strains (May/June); 4) Licensing of the vaccines by the National Control Authority (Paul-Ehrlich-Institute) (June/July); in the case of previously licensed products, the procedure is limited essentially to the approval of the detailed protocol of production and tests on the new virus strains, clinical studies not being required before licensing because of a lack of time; 5) Paul-Ehrlich-Institute's test for batch release, according to Directive 89/342/EEC, besides protocol approval, conducts material testing of the endotoxin and antigen content of each vaccine lot; the assay for the antigen quantification is especially laborious and sometimes must be repeated because of test invalidity.     

恶性疟P190抗原保守区Ⅰ、Ⅴ基因的亚克隆及在大肠杆菌中高效表达

作者采用PCR方法克隆了我国海南省FCC1/HN株P190抗原两个保守区基因,分别定名为P190CRI和P190CRV。基因片段经纯化后连接到pUC18载体中进行DNA序列分析,结果显示:除了P190CRV中有5个碱基变换外,其余序列均与MAD20型序列一致。经序列分析的两个基因片段分别与pGEX-2T载体连接,经双酶切鉴定后转化感受态JM109(DE_3)大肠杆菌进行高效融合表达,并且用Sepharose 4B-谷胱甘肽层析柱进行亲和纯化,结果为:两个插入基因片段均得到高效融合表达,经一步亲和纯化后就取得高纯度的重组蛋白。     

Dendritic Cells Coinjected with Tumor Cells Treated with an Anticancer Drug to Induce Tumor Rejection

Purpose: We examined whether bone marrow-derived dendritic cells (DCs) could induce antitumor immunity when a chemotherapeutic drug was added. Methods: CT26 (a murine colon cancer cell line syngeneic with BALB/c) and CT26-bearing mice were treated with mitomycin C (MMC) intraperitoneally (i.p.). Next, mice immunized with a coinjection of DCs and MMC-treated CT26 (i.p.) were given an intradermal inoculation of CT26. Finally, CT26-bearing mice were treated with MMC (i.p.) with or without DCs, given peritumorally. Results: Although the inoculated tumor was not rejected in the control mice, CT26 was rejected in 50% of the mice injected with MMC alone. Apoptosis was observed in the MMC-treated CT26 cells in vitro and in vivo. Immunization with DCs and apoptotic CT26 cells, but not with apoptotic CT26 alone, gave protection against tumor challenge in 7 of 13 mice. A significantly higher level of cytotoxic T-cell activity and interferon-γ production was seen in the protected mice. When MMC (i.p.) treatment was followed by peritumoral DC injection in the CT26-bearing mice, remarkable therapeutic effects were observed. Conclusion: DCs can collaborate with chemotherapy-induced apoptotic tumor cells and elicit improved antitumor immunity, probably through the acquisition of tumor-associated antigens from apoptotic tumor cells. Received: January 7, 2002 / Accepted: September 3, 2002 Acknowledgments. We thank Dr. Kazuo Kinoshita for his useful advice on using flow cytometry. This research was partly supported by the Ministry of Education, Culture, Sports, Science and Technology (No. 11671160). Reprint requests to: S. Yamasaki     

小剂量卡介苗、丝裂霉素交替灌注预防浅表性膀胱癌术后复发

目的 观察小剂量卡介苗(BCG)、丝裂霉素C(MMC)交替灌注预防浅表性膀胱癌术后复发的疗效和安全性。方法 回顾性分析自2000年5月～2001年6月的45例浅表性膀胱癌患的临床资料，29例行膀胱部分切除术，16例行经尿道膀胱肿瘤电切术(TuRBt)，术后定期应用卡介苗60mg、丝列霉素C 10mg交替膀胱灌注，每周1次共6次，间歇3个月，再每月1次，持续12个月。其中Ta、T1期22例、T2期23例。结果 所有病人随访12～24个月，45例患中，共有2例复发，均为TURBt后T2病人，总有效率95．2％，无全身不良反应，仅2例应用BCG后出现轻度膀胱刺激症状。结论 小剂量MMC、BCG交替膀胱内灌注，预防浅表性膀胱癌术后复发，效果好、病人耐受性强、副作用小。     

合肥地区献血员感染HBV和HCV危险因素的多因素分析

用ＥＬＩＳＡ法检测了合肥地区１４４０名献血员抗ＨＣＶ和乙肝五项指标，抗ＨＣＶ阳性率为５５％；ＨＢｓＡｇ携带率为１５％，ＨＢＶ总感染率４３７％。分别以抗ＨＣＶ阳性与感染过ＨＢＶ的献血员为病例，以抗ＨＣＶ阴性与未感染ＨＢＶ的献血员为对照进行了ＨＣＶ和ＨＢＶ感染危险因素的单因素和多因素分析。结果显示，ＡＬＴ、献血次数、献血量、文化程度、献血员心理和输血史与ＨＣＶ感染有关；血型、家庭人口数和家庭子女数与ＨＢＶ感染有关。     

Effects of hammerhead ribozyme (RCP) on HBV P gene in vitro

Ｅｆｆｅｃｔｓｏｆｈａｍｍｅｒｈｅａｄｒｉｂｏｚｙｍｅ（ＲＣＰ）ｏｎＨＢＶＰｇｅｎｅｉｎｖｉｔｒｏＧａｎＬｉｘｉａ（甘立霞），ＷａｎｇＰｉｎｇ（王平），ＺｈｕＸｉｈｕａ（朱锡华），ＤｏｎｇＹａｎｌｉｎ（董燕麟），ＨｏｕＹｕｎｄｅ（侯云德）（Ｄｅｐａｒ...     

Comparative vaccination of cattle against Boophilus microplus with recombinant antigen Bm86 alone or in combination with recombinant Bm91

Cattle were vaccinated either with a single recombinant tick antigen, Bm86 or with a combination of two recombinant antigens, Bm86 and Bm91 from the tick Boophilus microplus . In three experiments, the responses of cattle to subsequent challenge with the tick were assessed. The addition of the Bm91 antigen enhanced the efficacy of the vaccination over that with Bm86 alone to a statistically significant degree. Moreover, co-vaccination with two antigens did not impair the response of cattle to the Bm86 antigen. Finally, responses of individual cattle to the two antigens were independent. All of these results may be relevant to the increase in efficacy expected from a dual antigen vaccine.     

原位PCR检测肾组织内的乙型肝炎病毒

采用原位ＰＣＲ技术检测了肾小球肾炎患者活体组织。证实乙型肝炎病毒＜ＨＢＶ＞相关性肾脏中ＨＢＶ的存在。从分子病理学水平为探讨ＨＢＶ相关性肾炎发病机理提供了新的依据。     

江苏省肾综合征出血热单价灭活疫苗中期免疫效果观察

观察HFRS单价灭活疫苗中期免疫效果。方法：采用IFAT法及MCPENT法检测荧光抗体及中和抗体。结果：3个试区加强接种人数分别为4052、4407和6354人。加强后，Ⅰ型苗荧光抗体阳性率为72．73％，GMT为14.14；中和抗体阳性率为54．55％，GMT为6．67。D型苗荧光抗体阳性率为75.00％，GMT为11.85；中和抗体阳性率为60％，GMT为9．44。加强后1年，Ⅰ型苗年均保护率为65．52％，Ⅱ型苗则为94．24％。同期，Ⅰ型苗荧光抗体阳性率维持在40％，中和抗体维持在35．00％；Ⅱ型苗荧光抗体阳性率降至10．34％，中和抗体维持在53．85％。结论：两型疫苗均有较好的中期防病效果。